Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Sight Sciences (SGHT) stock in plain English

Free brief · no signupStart here
SGHTPublished Nov 17, 2026
Sight Sciences Inc
Healthcare · Medical Devices
Manufactures surgical devices that restore natural fluid outflow to lower eye pressure in glaucoma patients.
Assets:
OMNI Surgical Systemglaucoma device for canaloplasty and trabeculotomy
TearCare Systemwearable thermal device treating evaporative dry eye
Menlo Park baseCalifornia executive offices and product development hub
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
-1.39%$10.62
$590.25M
n/a (loss)
$88.36M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was SGHT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Sight Sciences (SGHT) do?

Sight Sciences Inc (SGHT) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures surgical devices that restore natural fluid outflow to lower eye pressure in glaucoma patients. Develops handheld devices that restore natural drainage pathways to treat glaucoma and dry eye conditions. It is worth $590.25M on the market and sold $88.36M over the last year.

Market cap
$590.25M
P/E ratio
None (reported a loss)
Annual sales
$88.36M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 17, 2026

Brands and businesses behind SGHT

  • OMNI: A handheld device used during glaucoma surgeries that generates revenue from sales of single-use units.
  • TearCare: A wearable eyelid heating device that generates sales from both reusable controllers and disposable treatment pads.
  • SION: A bladeless surgical instrument that earns revenue from disposable tool sales for micro-invasive trabeculotomy procedures.

SGHT’s flags, in plain English

Each flag is a number from Sight Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 87.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Insiders Hold

Insiders own 34.9% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -32.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about SGHT

How big is Sight Sciences?

Sight Sciences’ market cap is $590.25M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $88.36M: what customers paid the company over the last year, before any costs.

What is SGHT’s P/E ratio?

SGHT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with SGHT?

Medicare coverage determinations and local contractor pricing decisions directly dictate patient access and surgical utilization of canaloplasty procedures. That is one risk on Sight Sciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Sight Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SGHT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card